Table 1.
Demographic and clinical characteristics of SPAA and CCB+statin primary prevention patients
| SPAA | CCB+Statin | ||||
|---|---|---|---|---|---|
| Characteristic | (N = 1,537) | (N = 17,910) | p-value | ||
| Age: (Years) | |||||
| Mean | 53.5 | 54.8 | <.001 | ||
| SD | 7.6 | 8.5 | |||
| Median | 55 | 55 | |||
| Age group: (n,%) | <.001 | ||||
| <50 years | 412 | 26.8% | 4,119 | 23.0% | |
| 50-59 years | 816 | 53.1% | 9,636 | 53.8% | |
| 60+ years | 309 | 20.1% | 4,155 | 23.2% | |
| Gender: (n,%) | |||||
| Male | 900 | 58.6% | 9,327 | 52.1% | <.001 |
| Geographic Region: (n,%) | <.001 | ||||
| Northeast | 525 | 34.2% | 4,705 | 26.3% | |
| Midwest | 389 | 25.3% | 7,314 | 40.8% | |
| South | 595 | 38.7% | 5,296 | 29.6% | |
| West | 28 | 1.8% | 595 | 3.3% | |
| Plan Type: (n,%) | <.001 | ||||
| Health Maintenance Organization (HMO) | 311 | 20.2% | 6,429 | 35.9% | |
| Indemnity Plan | 92 | 6.0% | 885 | 4.9% | |
| Point of Service (POS) | 217 | 14.1% | 2,313 | 12.9% | |
| Preferred Provider Organization (PPO) | 884 | 57.5% | 7,805 | 43.6% | |
| Unknown | 33 | 2.1% | 478 | 2.7% | |
| Payer Type: (n,%) | <.001 | ||||
| Commercial Plan | 1,462 | 95.1% | 16,121 | 90.0% | |
| Medicaid | 1 | 0.1% | 158 | 0.9% | |
| Medicare Risk | 26 | 1.7% | 1,086 | 6.1% | |
| Self-Insured | 38 | 2.5% | 464 | 2.6% | |
| Other/Unknown | 10 | 0.7% | 81 | 0.5% | |
| Charlson Comorbidity Burden: | |||||
| Mean | 0.4 | 0.5 | <.001 | ||
| SD | 0.7 | 0.8 | |||
| Comorbid Conditions of Interest: (n,%) | |||||
| Diabetes Mellitus | 363 | 23.6% | 5,242 | 29.3% | <.001 |
| Dyslipidemia | 1,188 | 77.3% | 12,217 | 68.2% | <.001 |
| Obesity | 76 | 4.9% | 1,063 | 5.9% | 0.112 |
| Peripheral Vascular Disease | 35 | 2.3% | 476 | 2.7% | 0.371 |
| Chronic Obstructive Pulmonary Disease | 39 | 2.5% | 638 | 3.6% | 0.035 |
| Number of Pre-Index Unique Prescriptions: | <.001 | ||||
| 1-2 | 252 | 16.4% | 1,847 | 10.3% | |
| 3-4 | 392 | 25.5% | 3,646 | 20.4% | |
| 5-6 | 310 | 20.2% | 3,682 | 20.6% | |
| 7+ | 583 | 37.9% | 8,735 | 48.8% | |
| Number of Pre-Index Other Antihypertensive Classes: | <.001 | ||||
| 0 | 675 | 43.9% | 6,771 | 37.8% | |
| 1 | 718 | 46.7% | 9,237 | 51.6% | |
| 2 | 127 | 8.3% | 1,693 | 9.5% | |
| 3+ | 17 | 1.1% | 209 | 1.2% | |